NASDAQ · KYMR
Kymera Therapeutics, Inc.
$122.60+$0.09 (+0.07%)
Kymera Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.73% below the high.
Loading market information…
NASDAQ · ACLX · USD
Stock price, earnings
Quote as of May 15, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Arcellx, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Arcellx, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 | Aug 8, 2024 | -$0.51+5.56% vs estimate | $27.38M+24.27% vs estimate |
|---|
| Q1 2024 | May 9, 2024 | -$0.14+72.55% vs estimate | $39.26M+89.96% vs estimate |
|---|
THE ANALYST VIEW
18 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$122.60+$0.09 (+0.07%)
Kymera Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.73% below the high.
$62.61+$1.15 (+1.87%)
Vaxcyte, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.01% below the high.
$144.34+$2.20 (+1.55%)
Protagonist Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.24% below the high.
$60.49+$0.28 (+0.47%)
Arrowhead Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.65% below the high.
$45.37+$0.12 (+0.27%)
Alkermes plc’s quoted price sits in the upper half of its reported 52-week range, 18.5% below the high.
$29.64+$0.22 (+0.75%)
Immunovant, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.74% below the high.
$54.26+$0.15 (+0.28%)
CRISPR Therapeutics AG’s quoted price sits in the lower half of its reported 52-week range, 17.76% below the high.
$54.65$0.00 (0.0%)
Akero Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.42% below the high.
